SAN FRANCISCO, March 2, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation
The presentation will be accessible via a
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Jennifer Ruddock of Nektar Therapeutics415-482-5585
Jodi Sievers of Nektar Therapeutics415-482-5593
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-to-webcast-presentation-at-cowen-and-companys-37th-annual-health-care-conference-in-boston-300417511.html
SOURCE Nektar Therapeutics
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All